Tg Therapeutics (TGTX) EBIAT: 2016-2025
Historic EBIAT for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $390.9 million.
- Tg Therapeutics' EBIAT rose 9974.61% to $390.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $447.5 million, marking a year-over-year increase of 3215.24%. This contributed to the annual value of $23.4 million for FY2024, which is 84.52% up from last year.
- As of Q3 2025, Tg Therapeutics' EBIAT stood at $390.9 million, which was up 1,286.79% from $28.2 million recorded in Q2 2025.
- In the past 5 years, Tg Therapeutics' EBIAT ranged from a high of $390.9 million in Q3 2025 and a low of -$93.3 million during Q4 2021.
- Moreover, its 3-year median value for EBIAT was $5.1 million (2025), whereas its average is $41.8 million.
- In the last 5 years, Tg Therapeutics' EBIAT tumbled by 96.59% in 2024 and then surged by 9,974.61% in 2025.
- Tg Therapeutics' EBIAT (Quarterly) stood at -$93.3 million in 2021, then grew by 15.93% to -$78.5 million in 2022, then soared by 81.63% to -$14.4 million in 2023, then surged by 261.84% to $23.3 million in 2024, then soared by 9,974.61% to $390.9 million in 2025.
- Its last three reported values are $390.9 million in Q3 2025, $28.2 million for Q2 2025, and $5.1 million during Q1 2025.